Lunit's AI Demonstrates Up to 70% Workload Reduction and Enhanced Accuracy in Breast Cancer Screening: Study in European Radiology Reveals
- Employing Lunit INSIGHT MMG, a Turkish study showcases 70% efficiency improvements, advancements in early cancer detection, and interval cancer detection in mammography SEOUL, South Korea, April 8, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cance...
Lunit to Showcase 7 Studies at AACR 2024: Unveiling AI Innovations in HER2 Expression-Mutation Analysis and CNTN4 Biomarker Identification
- Lunit's AACR 2024 presentations to spotlight HER2 mutation insights and CNTN4's role in immunotherapy success, pioneering next-gen personalized treatment approaches, supported by the AI-powered Lunit SCOPE suite SEOUL, South Korea, April 1, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading...
Lunit SCOPE IO Reveals Promising Results in Neoadjuvant Immunotherapy Study for Head and Neck Cancer Patients
- New research published in Clinical Cancer Research shows significant improvement in distant recurrence-free survival with combined durvalumab and tremelimumab treatment, supported by Lunit SCOPE IO's analysis of tumor microenvironment SEOUL, South Korea, March 26, 2024 /PRNewswire/ -- Lunit (K...
Lunit Expands Presence in Europe: to Deliver AI-powered Cancer Screening Solution to France and Portugal
* New supply contract to bring Lunit INSIGHT CXR to TeleDiag in France and Lunit INSIGHT MMG to the Central region branch of the Portuguese League Against Cancer SEOUL, South Korea, March 18, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diag...
Lunit SCOPE AI Enhances Pathologist Concordance and Accuracy in HER2, ER, and PR Assessment - New Study in Breast Cancer Research
- Lunit SCOPE HER2 and Lunit SCOPE ER/PR significantly improve pathologist concordance and accuracy, paving the way for improved breast cancer molecular subtype analysis for informed decision-making and precision patient care SEOUL, South Korea, March 14, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ...
Update on Lunit's Acquisition of Volpara: New Zealand High Court Initial Approval Secured
- Volpara shareholder meeting to be held on April 12, 2024: Culminating the acquisition journey for Lunit, finalization set for May SEOUL, South Korea, March 13, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today ...
Lunit Presents Seven Study Results at ECR 2024: Showcasing AI's Robust Performance in Diverse Clinical Settings
- Lunit to unveil four oral presentations and three poster presentations at ECR 2024, highlighting Lunit INSIGHT's expansive capability, ranging from adaptability in different use cases to the potential to replace a human reader in mammography double-reading settings SEOUL, South Korea, Feb. 28...
New Study Demonstrates Predictive Value of Lunit SCOPE IO to Predict Outcomes of Immune Checkpoint Inhibitor Therapy Across Diverse Tumors - published in the JITC
- A new study published in the Journal for ImmunoTherapy of Cancer (JITC) shows that Lunit's AI-powered biomarker "Lunit SCOPE IO" can predict favorable outcomes of Inflamed Immune Phenotype patients treated with Immune Checkpoint Inhibitor across multiple cancer types SEOUL, South Korea, Feb. ...
Lunit INSIGHT CXR Excels in Lung Nodule Detection - Exceptional Performance in Head-to-Head Study published in Radiology
- Lunit's AI-powered chest X-ray analysis solution shows highest AUC of 0.93 in a recent multi-center, multi-use case, multi-vendor lung nodule detection study SEOUL, South Korea, Jan. 17, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostic...
Lunit AI Solutions to Power Samsung's X-ray Devices for Advanced Chest Screening
* Three-year supply contract: Lunit INSIGHT CXR and Lunit INSIGHT CXR Triage to enhance lung abnormality detection in Samsung's premium X-ray devices SEOUL, South Korea, Jan. 16, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and t...
Lunit to Acquire Volpara: Scheme Implementation Agreement Signed
- Lunit's strategic global leap: to acquire all of Volpara shares at AUD 1.15 per share, envisioning completion by Q2 2024 SEOUL. South Korea, Dec. 14, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced ...
Lunit Advances to Stage 2 of Australia's National Breast Cancer Screening Project
* After a successful stage 1, Lunit INSIGHT MMG moves to prospective validation inAustralia's BreastScreen NSW Machine Reading Solution Project SEOUL, South Korea, Dec. 11, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therape...
Lunit to Advance Singapore's Healthcare System with AI-powered Solution for Medical Imaging
* Lunit INSIGHT CXR is piloted at Singapore General Hospital and Changi General Hospital through AimSG, a national medical imaging AI platform for Singapore's Public Healthcare SEOUL, South Korea, Nov. 30, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions fo...
AI-Powered TIL Analysis by Lunit Unveils Prognostic Insights for Colon Cancer - published in npj Precision Oncology
* AI-powered spatial analysis of tumor-infiltrating lymphocytes using Lunit SCOPE IO provides accurate prognosis prediction in stage II–III colon cancer SEOUL, South Korea, Nov. 27, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and...
Lunit's AI-Powered Mammography Analysis Solution Proves Comparable to Radiologists in Breast Cancer Detection - published in European Radiology
- A large population-based retrospective study in Denmark validates that Lunit INSIGHT MMG's accuracy is on par with that of radiologists in detecting breast cancer SEOUL, South Korea, Nov. 22, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diag...
Lunit to Implement AI-Powered Chest Screening Solution in Five Major Saudi Hospitals
- Lunit brings Lunit INSIGHT CXR to five major Saudi hospitals, aiming to enhance early detection of common lung abnormalities and improve patient outcomes in line with the national health strategy SEOUL, South Korea, Nov. 16, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of ...
Lunit Secures $150 Million in Capital Increase
* Fund fully paid-in as of November 9, achieving over 100% shareholder participation SEOUL, South Korea, Nov. 15, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the successful completion of a signi...
Lunit Nets FDA Nod for AI-Powered 3D Breast Tomosynthesis Solution, Lunit INSIGHT DBT
- Lunit INSIGHT DBT receives FDA 510(k) clearance, poised to enter the world's largest DBT market SEOUL, South Korea, Nov. 14, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced that it has received U.S....
Lunit, a Founding Member of CancerX, Showcased in the Inaugural Project to Improve Equity and Reduce Financial Toxicity in Cancer Care
- Lunit INSIGHT suite, Lunit's AI-driven solutions for early detection of cancer, featured in CancerX's first official project: enhancing equity and reducing financial burden in cancer care SEOUL, South Korea, Nov. 13, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered ...
Lunit to Present Seven AI-Powered Radiology Studies at RSNA 2023
* Two oral presentations and five ePosters accepted by the RSNA: presenting AI advancements for chest radiograph reporting efficiency and breast cancer risk assessment SEOUL, South Korea, Nov. 6, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer ...
